Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alnylam Pharmaceuticals, Inc.
Alnylam Grants KOKEN License to Kreutzer-Limmer Patents for the RNA Interference RNAi Research Products Market
November 11th, 2009
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and KOKEN Co., Ltd., a leading atelocollagen company, announced that Alnylam has granted KOKEN a non-exclusive worldwide license to manufacture and provide RNAi research products and services under the Kreutzer-Limmer patent family. This patent family, owned exclusively by Alnylam, covers fundamental aspects of the structure and uses of RNAi products, including small interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells, and of RNAi-related mechanisms. "We are pleased to grant KOKEN a license to manufacture and provide siRNA reagents to its industry and academic...
Source: Medical Patent Law Weekly (2009-11-11)
|
